A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.

Abstract

In an open pilot study, 10 patients with Parkinson's disease and nocturnal and/or early-morning disabilities were given Madopar HBS (hydrodynamically balanced system; mean dose 250 mg) shortly before retiring in addition to their usual daytime antiparkinsonian treatment. Eight patients derived worthwhile improvement; the most gratifying responses were seen in the relief of nocturnal bradykinesia, rigidity and tremor. Early-morning symptoms were also improved in 3 out of 5 patients, possibly as a secondary response to an improved nights sleep. Cramps, early-morning dystonia and pain, however, responded poorly. Overall results are sufficiently encouraging to warrant further controlled studies with Madopar HBS in what has been a relatively neglected area of distress for many patients with Parkinson's disease.

• Authors: A J Lees
• Journal: European neurology (Eur Neurol) Vol. 27 Suppl 1 Pg. 126-34 ( 1987) ISSN: 0014-3022 [Print] Switzerland
• PMID: 3428306 (Publication Type: Journal Article)

Chemical References

• Delayed-Action Preparations
• Drug Combinations
• Hydrazines
• benserazide, levodopa drug combination
• Levodopa
• Benserazide

Topics

• Benserazide (pharmacokinetics, therapeutic use)
• Circadian Rhythm
• Delayed-Action Preparations
• Drug Combinations (pharmacokinetics, therapeutic use)
• Female
• Humans
• Hydrazines (therapeutic use)
• Levodopa (blood, pharmacokinetics, therapeutic use)
• Male
• Middle Aged
• Movement Disorders (drug therapy, etiology)
• Parkinson Disease (complications, drug therapy, physiopathology)